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SUMMARY
Vascular endothelium is a dynamic cellular interface that displays a unique phenotypic plasticity. This plasticity is critical for vascular
function and when dysregulated is pathogenic in several diseases. Human genotype-phenotype studies of endothelium are limited by
theunavailabilityofpatient-speciﬁcendothelialcells.Toestablishacellularplatformforstudyingendothelialbiology,wehavegenerated
vascular endothelium from human induced pluripotent stem cells (iPSCs) exhibiting the rich functional phenotypic plasticity of mature
primary vascular endothelium. These endothelial cells respond to diverse proinﬂammatory stimuli, adopting an activated phenotype
including leukocyte adhesion molecule expression, cytokine production, and support for leukocyte transmigration. They maintain dy-
namicbarrierpropertiesresponsivetomultiplevascularpermeabilityfactors.Importantly,biomechanicalorpharmacologicalstimulican
induce pathophysiologically relevant atheroprotective or atheroprone phenotypes. Our results demonstrate that iPSC-derived endothe-
lium possesses a repertoire of functional phenotypic plasticity and is amenable to cell-based assays probing endothelial contributions to
inﬂammatory and cardiovascular diseases.
INTRODUCTION
The vascular endothelium, the single-cell layer lining
blood vessels, is a multifunctional interface that displays
a striking phenotypic plasticity necessary for maintaining
vascular homeostasis. In this context, the vascular endo-
thelium is critical to initiate an inﬂammatory response,
trigger thrombosis, regulate vasomotor tone, and control
vascular permeability. Dysfunction of the endothelium
plays a signiﬁcant pathogenic role in cardiovascular dis-
eases, namely, atherosclerosis and its consequences: heart
attacks and strokes (Gimbrone et al., 2000; Hansson,
2005). Notably, studies at the genetic and molecular level
of human endothelium have been limited by the availabil-
ity of relevant tissue derived from cadaveric, discarded sur-
gical, or umbilical vasculature sources.
Recent developments in stem cell biology promise new
resources for modeling genetic diseases. In particular,
induced pluripotent stem cells (iPSCs) offer the ability to
study the effects of genetic alterations and mechanisms
ofgeneticdiseasesincurrentlyinaccessiblecelltypes(Taka-
hashi and Yamanaka, 2006). Although iPSCs have been
differentiated into many cell types including endothelium
(Choi et al., 2009; Homma et al., 2010; Li et al., 2011; Park
et al., 2010; Rufaihah et al., 2011, 2013; Taura et al., 2009;
White et al., 2013), the ﬁdelity and functional mimicry of
stem cell-derived tissues and their relevance to human dis-
ease remain poorly characterized. This functionality must
be carefully assessed before their scientiﬁc and therapeutic
potential can be realized (Soldner and Jaenisch, 2012).
The goals of this study were to reproducibly generate
human iPSC-derived vascular endothelial cells (iPSC-ECs)
and to then assess whether they could acquire speciﬁc
functions critical for vascular homeostasis displayed by pri-
maryculturesofhumanvascularendothelium.Tothisend,
we differentiated human iPSCs as embryoid bodies (EBs)
and isolated the endothelial population for detailed func-
tional characterization. Signiﬁcantly, in addition to dis-
playing characteristic endothelial molecular and structural
features, these ECs display phenotypic plasticity that
allows them to mediate leukocyte transmigration and
maintain a dynamic barrier. Furthermore, we have docu-
mented that the iPSC-ECs can be directed to acquire an
atheroprotective or atheroprone phenotype in response
to distinct biomechanical or pharmacological stimuli.
Collectively, our results demonstrate that human iPSC-
ECs support a spectrum of physiological endothelial func-
tions and possess the relevant phenotypic plasticity to
probe important features of human cardiovascular patho-
physiology in a patient-speciﬁc manner.
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Human iPSC Differentiation into Vascular
Endothelium
To generate ECs, we differentiated iPSCs of the BJ1 cell line
as EBs in suspension by replacing iPSC medium with differ-
entiation medium containing fetal calf serum. The speciﬁc
serum chosen was selected from a screen optimizing prolif-
eration and morphology of cultured human ECs (data not
shown).To carefully characterize the timescale of EC differ-
entiation, we performed quantitative real-time TaqMan
PCR using RNA harvested daily from EBs from the time of
their generation from iPSC colonies, day 0, through
18 days of differentiation. Under these conditions, we
observed increasing expression of EC markers CDH5
(VE-cadherin), KDR (VEGFR2), and CD31 (PECAM1) (Fig-
ure 1A). To better deﬁne the EC population, we measured
the expression of VE-cadherin, CD31, and KDR by ﬂow
cytometry within dissociated EBs after different durations
of differentiation. As seen in Figure 1B, the VE-cadher-
in
+jCD31
+ EC fraction peaked at 18% ± 4% (mean ± SD)
of the EBs after 10 days of differentiation. The EBs grew
in large cystic tissues containing cord-like structures (Fig-
ure 1C). Two-photon confocal microscopy visualized ﬂuo-
rescently labeled VE-cadherin within the intact  1m m
diameter EBs indicating that most VE-cadherin
+ cells reside
in networked structures (Figure 1D).
Because the proportion of VE-cadherin
+jCD31
+ cells
peaks at day 10, we isolated the EC population (iPSC-EC)
from dissociated day 10 EBs for further analysis. Due
to its endothelial speciﬁcity and to the presence of
CD31
+jVE-cadherin
 , CD31
+KDR
 , and CD31
 jKDR
+ cells
withintheEBs(Figure1E,leftandcenterpanels)anddueto
the fact that a subpopulation of CD31
+ cells expresses
CD45 (Figure S1A available online), we chose to isolate
ECs based on VE-cadherin expression. Magnetic bead sort-
ing produced a population with greater than 95% VE-cad-
herin
+ cells (Figure 1E, right panel). To ensure that this
endothelial differentiation protocol is generalizable, we
tested additional human iPSC lines generated with
different technologies. Importantly, each cell line was
reproducibly able to generate ECs, although with different
yields (Figure 1F).
Next, we assessed whether isolated iPSC-ECs exhibit
characteristic EC molecular markers and cellular behavior
after in vitro culture. As seen in Figures 1G–1M, iPSC-ECs
displayed typical cobblestone morphology, expressed
VE-cadherin and CD31 at cell junctions, expressed
VE-cadherin, KDR, and thrombomodulin on their cell sur-
face, expressed endothelial nitric oxide synthase (eNOS) at
the perinuclear region and plasma membrane, endocy-
tosed ﬂuorescent acetylated LDL, and could form networks
on Matrigel in the presence of VEGF.
We also observed that iPSC-ECs displayed punctate von
Willebrand factor (vWF) and angiopoietin-2 staining (Fig-
ure S1B). Because vWF and angiopoietin-2 are normally
stored in endothelia-restricted organelles termed Weibel-
Palade bodies (WPBs), we investigated via electron micro-
scopy the presence of these organelles in iPSC-ECs. We
identiﬁed electron-dense striated structures typical of
WPBs that stained for vWF by immunogold labeling (Fig-
ure S1B). Functionally, WPBs store and rapidly exocytose
vWF and P-selectin to initiate a hemostatic response (Wag-
ner and Frenette, 2008). In order to verify that the WPBs
were competent for rapid exocytosis, we treated the iPSC-
ECs with histamine and observed rapid and transient pre-
sentation of P-selectin to the cell surface (Figure S1B).
Proinﬂammatory Endothelial Activation
After documenting essential molecular features of vascular
endothelium, we investigated whether iPSC-ECs can
display multiple functional phenotypes characteristic of
mature endothelium. A pathophysiologically essential
property of endothelium is the response to proinﬂamma-
tory stimuli and participation in inﬂammatory responses.
To assess this activated functional phenotype, we exposed
iPSC-ECs to the proinﬂammatory stimuli, interleukin-1
beta (IL-1b), tumor necrosis factor alpha (TNF-a), and
Figure 1. Derivation of iPSC-ECs
(A) Gene expression time proﬁles of CDH5 (VE-cadherin), KDR, and CD31 measured by quantitative real-time PCR (n = 3) with the asterisks
(*) denoting values different than day 0 (p < 0.05).
(B) CD31, VE-cadherin, and KDR expression in EB cells measured by ﬂow cytometry (n = 3).
(C) Phase-contrast image of an EB after 10 days of differentiation.
(D) Reconstruction of two-photon confocal microscopy images of VE-cadherin (green) and nuclei (blue) within an EB after 10 days of
differentiation.
(E) The isolation of VE-cadherin
+ cells from the EB with magnetic bead sorting.
(F–M)FractionofEBcellsexpressingVE-cadherinfromdifferentiPSClines(F;n=4).IsolatediPSC-ECscharacterizedbyphasecontrast(G),
immunoﬂuorescenceforVE-cadherin(H)andCD31(I),ﬂowcytometry(J)forVE-cadherin,KDR,andthrombomodulin(sampleinsolidline;
isotype control in dotted), immunoﬂuorescence for eNOS (K) and endocytosed acetylated-LDL (L), and a phase-contrast image of the
network formation on Matrigel (M).
All pooled data are represented as mean ± SD.
See also Figure S1.
Stem Cell Reports j Vol. 1 j 105–113 j August 6, 2013 j ª2013 The Authors 107
Stem Cell Reports
Functional Endothelium Derived from Human iPSClipopolysaccharide (LPS), and assessed the cell surface
expression of the adhesion molecules E-selectin, intercel-
lularadhesionmolecule1(ICAM-1),andvascularcelladhe-
sion molecule 1 (VCAM-1), critical for endothelial-leuko-
cyte interactions (Figure 2A; for ﬂuorescence intensity
values, see Figure S2A). After 6 hr, IL-1b, TNF-a, and LPS
induced the expression of E-selectin and ICAM-1 in the
majority of the cell population, and of VCAM-1 in a frac-
tion. After 24 hr of IL-1b, TNF-a, or LPS stimulation, the
iPSC-ECs expressed E-selectin to a lesser degree, and
ICAM-1 and VCAM-1. Additionally, treatment with inter-
feron-gamma (IFNg) induced the ECs to upregulate
ICAM-1 expression synergistically with TNF-a in a time-
dependent manner as reported in studies of primary EC
cultures (Doukas and Pober, 1990)( Figure S2B).
In addition to presenting adhesion molecules, the acti-
vated endothelial phenotype includes the secretion of
proinﬂammatory cytokines. Therefore, we examined
whether iPSC-ECs have this capability by measuring the
concentration of several proinﬂammatory cytokines in
the culture supernatant. Treatment for 24 hr with IL-1b,
TNF-a, or LPS induced the iPSC-ECs to secrete monocyte
chemotactic protein-1 (MCP1), IL-8, RANTES, and IFNg-
induced protein 10 (IP10), potent chemoattractants that
act on T cells, neutrophils, and monocytes (Figure 2B),
whereas treatment with IFNg induced the ECs to secrete
IP10 and monokine induced by gamma interferon (MIG).
Importantly, the coordinated expression of adhesion
molecules and secretion of proinﬂammatory cytokines by
thevascularendotheliumorchestratesthetransendothelial
migration of leukocytes. The iPSC-ECs, after treatment for
4 hr with 10 ng/ml TNF-a, were able to coordinate the inte-
grated behavior of inducing human neutrophil and T
lymphocyte rolling, arrest, and transmigration under
laminar ﬂuid ﬂow (Figure 2C; Movies S1 and S2). The frac-
tions of transmigrating leukocytes were similar to those
seen with primary HUVECs, the human model currently
most commonly used for leukocyte transmigration studies
(Figure 2D). It is important to note that this transmigration
was dependent on T lymphocyte and neutrophil b2-integ-
rin (CD18) and on endothelial ICAM-1 as demonstrated by
the diminished transmigration in the presence of relevant
blocking antibodies (Figures 2E–2H) similar to primary ECs
(Rao et al., 2007).
Maintenance of a Dynamic Barrier
A critical function ofthe vascular endothelium is the main-
tenance of a tight dynamic barrier to contain the blood’s
plasma and cellular constituents. ECs actively rearrange
junctional and cytoskeletal proteins to modulate their bar-
rier function in response to multiple physiological stimuli
(Dejana et al., 2001; Mehta and Malik, 2006). To charac-
terize the barrier phenotype of iPSC-ECs, we examined
the role of known EC permeability factors on the electrical
resistance across a monolayer of iPSC-ECs, a real time mea-
sure of permeability. As seen in Figure 3A, histamine
induced a transient increase in permeability, whereas
VEGF induced a sustained increase in permeability, which
was partially abrogated by pretreatment with a FAK inhib-
itor (Figure S3A), as demonstrated in primary endothelium
(Chen et al., 2012). Prostaglandin E2 produced a decrease
in permeability as did sphingosine-1-phosphate. Treat-
ment of iPSC-ECs with the cAMP analog, 8-pCPT-20O-Me-
cAMP (O-Me) that selectively activates Epacs (Bos, 2006),
induced a sustained decrease in permeability as reported
in primary ECs (Cullere et al., 2005). Compared to
HUVECs, the iPSC-ECs display a lower VEGF-induced
permeability and slower response to O-Me (Figure S3B).
We next documented the rearrangements of structural pro-
teins that modulate barrier properties (Mehta and Malik,
2006). As seen in Figure 3B, we found that treatment
with O-Me resulted in redistribution of VE-cadherin from
a jagged to a more linear geometry and favored the genera-
tion of actin ﬁlaments at the cell periphery over longitudi-
nal actin ﬁlaments, as seen in primary ECs (Cullere et al.,
2005).
Directing Phenotypic Plasticity to Disease-Protective
and -Prone States
A promising application of iPSC-derived endothelium is
the ability to study endothelium in pathophysiologically
relevant states in a patient-speciﬁc manner. Therefore, we
evaluated whether iPSC-ECs are able to adopt atheroscle-
rosis-protective and atherosclerosis-prone phenotypes
in vitro, which are critical to enable their use in studies of
endothelial contributions to cardiovascular disease.
Distinct local hemodynamic environments have been
linked to the nonrandom predictable distribution of
atherosclerotic lesions in human and animal studies
(Chiu and Chien, 2011; Gimbrone and Garcı ´a-Carden ˜a,
2013). In fact, local biomechanical forces can strongly in-
ﬂuence endothelial phenotype and induce a functional
phenotype or one that is dysfunctional, an early step in
atherogenesis (Davies, 2009; Gimbrone, 1999; Hahn and
Schwartz, 2009). In particular, the speciﬁc shear stress pat-
terns exerted on ECs at the sites of atheroprotection and
atherosusceptibility in the human carotid artery induce
atheroprotective and atheroprone phenotypes respectively
in cultured ECs (Dai et al., 2004). In order to generate these
biomechanically induced phenotypes in iPSC-ECs, we
applied atheroprotective or atheroprone shear stress wave-
forms for 72 hr (Figure 4A). As seen in Figures 4B and 4C,
the iPSC-ECs selectively responded to atheroprotective
ﬂow by aligning in the direction of ﬂow, whereas those
exposed to atheroprone ﬂow did not. A key molecular
descriptor of the endothelial atheroprotective versus
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factors Kruppel-like factors 2 (KLF2) and 4 (KLF4), integra-
tors of the ﬂow-mediated vasoprotective phenotype (Dek-
ker et al., 2006; Parmar et al., 2006; Villarreal et al., 2010).
Thus, we measured the expression of these genes in iPSC-
ECs exposed to atheroprotective or atheroprone shear
Figure 2. Assessment of Endothelial Activation in iPSC-ECs
(A) Surface expression of E-selectin, ICAM-1, and VCAM-1 after 6 or 24 hr of 10 U/ml IL-1b, 10 ng/ml TNF-a,o r1mg/ml LPS treatment
measured by ﬂow cytometry.
(B) Culture supernatant concentration of chemokines after 24 hr treatment of TNF-a, IL-1b, IFNg, LPS, or TNF-a+IFNg with the asterisks
(*) indicating difference to vehicle (veh) (p < 0.05; n = 3–4).
(C) Time proﬁle of transmigrated neutrophils and T cells after 4 hr TNF-a treatment.
(D) Fraction of neutrophils or T cells transmigrated across TNF-a- stimulated iPSC-ECs and HUVECs (n = 3; n.s., not signiﬁcant).
(E–H) Transmigration of neutrophils after pretreatment of neutrophils with anti-CD18 antibody (E) or pretreatment of iPSC-ECs with anti-
ICAM-1 antibody (F). Transmigration of T cells after pretreatment of T cells with anti-CD18 antibody (G) or pretreatment of iPSC-ECs with
anti- ICAM-1 antibody (H). A binding nonblocking anti-MHC class I antibody was used as a control (n = 2).
All pooled data are represented as mean ± SD.
See also Figure S2 and Movies S1 and S2.
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waveform differentially induced the expression of KLF2
and KLF4 (Figure 4D). Furthermore, we measured the
expression of several other mechano-activated genes and
downstream effectors of KLF2 and KLF4 and observed
that atheroprotective shear stress upregulates NOS3
(eNOS), argininosuccinate synthase 1 (ASS1), and downregu-
lates vWF. In contrast, atheroprone ﬂow upregulated
endothelin-1 (EDN1), a potent vasoconstrictor known to
be differentially regulated by ﬂow (Figure 4D).
In addition to biomechanical forces, ECs are responsive
to pharmacological agents. In particular, our laboratory
and others have documented that the endothelial athero-
protective phenotype and KLF2 expression can be evoked
by statins, a class of HMG-CoA reductase inhibitors (Par-
mar et al., 2005; Sen-Banerjee et al., 2005). To illustrate
that iPSC-ECs areasuitablesubstrate forpersonalized phar-
macological studies, we examined whether iPSC-EC
phenotype can be similarly modulated by statin treatment.
As seen in Figure 4E, simvastatin upregulated KLF2 expres-
sion as well as downstream effectors NOS3, ASS1, thrombo-
modulin (THBD), integrin beta 4 (ITGB4), and prostaglandin-
H2 D-isomerase (PTGDS). Simvastatin also downregulated
proinﬂammatory ANGPT2 and EDN1. The induction of
KLF2 and NOS3 in iPSC-ECs showed similar sensitivity to
simvastatin concentration as primary ECs (Figure S4).
DISCUSSION
In this study, we have generated vascular ECs from human
iPSCs and characterized their humoral-, pharmacological-,
and biomechanical-induced functional phenotypes,
advancing iPSC-ECs as an experimental platform to study
endothelial biology. The methodology to differentiate
iPSCs into vascular endothelium was reproducible and
robust across several iPSC lines created with different tech-
nologies. Previous studies have differentiated iPSCs to
Figure 3. Barrier Properties of iPSC-ECs
(A) Changes in transendothelial electrical resistance after treatment with 10 mM histamine, 100 ng/ml VEGF, 200 ng/ml prostaglandin E2,
0.5 mg/ml sphingosine-1-phosphate, or 100 mM O-Me. Data are represented as mean ± SD (n = 3) with the asterisks (*) denoting different
from control (p < 0.05). Arrows indicate time of addition of compound.
(B) VE-cadherin and actin after 24 hr treatment with 100 mM O-Me seen by immunoﬂuorescence microscopy.
See also Figure S3.
110 Stem Cell Reports j Vol. 1 j 105–113 j August 6, 2013 j ª2013 The Authors
Stem Cell Reports
Functional Endothelium Derived from Human iPSCisolate ECs based on expression of CD31 or KDR (Choi
et al., 2009; Homma et al., 2010; Li et al., 2011; Park
et al., 2010; Rufaihah et al., 2011, 2013; Taura et al.,
2009; White et al., 2013). In contrast, we isolated popula-
tionsofECsfromtheEBsbasedonVE-cadherinexpression,
a strong marker of endothelial identity, as we observed
CD31
+, and KDR
+ cells subpopulations lacking VE-cad-
herin, and a CD31
+ subpopulation expressing CD45.
Afterisolationandculture,iPSC-ECsdisplayedmolecular
markers of vascular endothelium and contained vWF-pos-
itive WPBs that can be rapidly exocytosed, a critical func-
tion for hemostasis. It is possible that the perinuclear
localization observed in many of the WPBs may suggest
an immature stage in WPB biogenesis (Valentijn et al.,
2011; Zenner et al., 2007). iPSC-ECs are competent for
the functional repertoire displayed by vascular endothe-
lium critical in pathophysiological settings. Speciﬁcally,
we demonstrated that proinﬂammatory stimuli induce an
activated proinﬂammatory phenotype that included
expression of leukocyte adhesion molecules, secretion of
proinﬂammatory cytokines, and support for human leuko-
cyte transmigration. We also observed that iPSC-EC mono-
layers display a dynamic permeability in response to a
panel of physiological stimuli.
Human iPSC-ECs are a promising platform for studying
endothelial contributions to cardiovascular diseases in
the context of speciﬁc patients’ genetic backgrounds. We
demonstrated that iPSC-ECs have the plasticity to acquire
Figure 4. Acquisition of Atheroprotective and Atheroprone Endothelial Phenotypes
(A–C) A single period of atheroprotective and atheroprone shear stress waveforms (A). iPSC-ECs imaged by phase contrast after 72 hr of
atheroprone (B) or atheroprotective ﬂow (C; arrow indicates direction of ﬂow).
(D) Relative (Rel.) gene expression after 72 hr of atheroprotective or atheroprone shear stress.
(E) Relative gene expression after 24 hr treatment with 10 mM simvastatin.
The asterisks (*) indicate statistical signiﬁcance with p < 0.05 (n = 4). All pooled data are represented as mean ± SD.
See also Figure S4.
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tective and atheroprone phenotypes critical for atheroscle-
rosis resistance and susceptibility. We observed that
iPSC-ECs respond to atheroprotective shear stress by acti-
vating an atheroprotective gene expression program tran-
scriptionally mediated by KLF2 and KLF4 expression,
shown to integrate the ﬂow-mediated endothelial athero-
protective functional phenotype by regulating leukocyte
adhesion, redox state, and thrombotic function in cultured
human ECs (Dekker et al., 2006; Lin et al., 2005; Parmar
et al., 2006; SenBanerjee et al., 2004; Villarreal et al.,
2010). The ability to direct the acquisition of ﬂow-depen-
dent functional and dysfunctional phenotypes using
patient-speciﬁcendotheliumshouldallowthestudyofspe-
ciﬁc genetic contributions to endothelial function and
dysfunction in the context of human cardiovascular dis-
ease. Furthermore, we demonstrated that simvastatin acti-
vated an atheroprotective gene expression program and
downregulated genes associated with an atheroprone
phenotype in iPSC-ECs. This suggests that iPSC-ECs may
be a suitable surrogate to assess the effects of drugs on the
endothelia of speciﬁc patients.
The ability to generate human vascular endothelium
from iPSCs is an enabling platform. Cell-based assays of
endothelial function can be combined with ECs derived
from iPSC lines produced from patients with genetic dis-
eases, creating powerful model systems of human disease
or associations where the pathological molecular mecha-
nisms and their functional consequences are poorly under-
stood (Adams and Garcı ´a-Carden ˜a, 2012; Grskovic et al.,
2011; Kiskinis and Eggan, 2010). Extension of these disease
iPSC-based assays to high throughput may enable the new
therapeutic discovery for genetic diseases and permit the
personalization of drug toxicity testing, an unmet need
because vascular toxicity is a signiﬁcant cause of attrition
in drug development.
EXPERIMENTAL PROCEDURES
Cell Culture
FourhumaniPSClineswereusedinthisstudy.LinesBJ1andMSC1
were received from the laboratory of Dr. George Q. Daley (Chil-
dren’s Hospital Boston), line BMC1 from the laboratory of Dr. Dar-
rell N. Kotton (Boston University Medical Center), and line DH1F
from the Harvard Stem Cell Institute.
Differentiation and Isolation of iPSC-ECs
Colonies of iPSCs were differentiated as EBs in suspension in ultra-
low adhesion plates (Corning) in differentiation medium for
10 days. EBs were dissociated into single cells with 2 mg/ml colla-
genaseB(Roche)for2hrthenCellDissociationBuffer(Invitrogen)
for 15 min at 37 C shaking at 1,100 rpm. VE-cadherin
+ cells were
isolated by magnetic bead sorting (Miltenyi Biotec) using PE-con-
jugated anti-VE-cadherin antibody (BD Biosciences) and magnetic
bead-conjugated anti-PE antibody (Miltenyi). Isolated iPSC-ECs
were plated at 20,000 cells/cm
2 on 50 mg/ml ﬁbronectin (Sigma-Al-
drich)-coated dishes in EC medium. Experiments were performed
on passage one.
Please see Table S1 for a list of TaqMan probes used in this study
and Table S2 for clones and vendors of primary antibodies.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, four ﬁgures, and two movies and can be found with
this article online at http://dx.doi.org/10.1016/j.stemcr.2013.06.
007.
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